Cellectar Biosciences Enrolls First Patient in Phase 1b Trial for CLR 125 Breast Cancer Treatment

Key Facts

1Cellectar Biosciences enrolled the first patient in its Phase 1b clinical trial of CLR 125.

2The drug targets refractory triple-negative breast cancer (TNBC) using Auger-emitting radioconjugate technology.

3The trial will evaluate safety, tolerability, and preliminary efficacy across three dose levels.

Cellectar Biosciences has officially enrolled the first patient in its Phase 1b clinical trial evaluating CLR 125 for the treatment of refractory triple-negative breast cancer (TNBC). The investigational drug utilizes innovative Auger-emitting radioconjugate technology designed to target aggressive cancer cells. This trial is structured to assess the safety, tolerability, and preliminary efficacy of the treatment across three distinct dose levels. The commencement of this study marks a significant clinical milestone for the company as it expands its oncology pipeline. By targeting TNBC, Cellectar aims to address a critical unmet medical need in the healthcare sector. This early-stage development is viewed as a positive operational step for the biotech firm, potentially driving long-term value for shareholders. The market will be closely monitoring the initial safety data and efficacy signals from this cohort.